Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20792210 | 1.00 | PNMT (0.67) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL9210534 | 0.87 | PNMT (0.60) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL14981092 | 0.84 | PNMT (0.56) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL1730002 | 0.84 | PNMT (0.56) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL30361288 | 0.84 | PNMT (0.60) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL18793794 | 0.84 | PNMT (0.60) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL2286649 | 0.84 | PNMT (0.56) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL3597792 | 0.84 | PNMT (0.60) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL3597789 | 0.84 | PNMT (0.60) | PNMTIDO1TDO2HTR2AHTR2C | |
| SCHEMBL29707581 | 0.84 | PNMT (0.56) | PNMTIDO1TDO2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| CN-111440205-B | Biboric acid diol ester, preparation method thereof, intermediate thereof and application thereof | 中国科学院上海有机化学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | disclosed |
| WO-2021072369-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | disclosed |
| CN-111440205-A | Biboric acid diol ester, preparation method thereof, intermediate thereof and application thereof | 中国科学院上海有机化学研究所 | 2020-07-24 | — | — | CN | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
| CN-102112451-B | Diazepan and piperazine derivatives modulators of chemokine receptors | HOFFMANN LA ROCHE | 2014-01-22 | — | — | CN | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2321285-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
| US-4129661-A | 4,5-Dihydro-2-lower alkoxycarbonylamino-4-phenylimidazoles and substituted phenyl derivatives thereof | SYNTEX (U.S.A.) INC. (US) | 1978-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | CFH, LPAR3, CBR3 | PNMT 3622/4885IDO1 3991/4885TDO2 1534/4885 |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | PNMT 4025/4885IDO1 4407/4885TDO2 4333/4885 |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | PNMT 3631/4885IDO1 1522/4885TDO2 3949/4885 |
| US-11168074-B2 | Potassium channel inhibitors | KCNN2, KCNJ2, KCNN1 | PNMT 3299/4885IDO1 4139/4885TDO2 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.